M&A Considerations Across the Evolving Life Sciences Sector

The life sciences M&A landscape in the first quarter of 2026 was defined by constrained capital markets, heightened investor selectivity, and increasingly sophisticated transaction structures. With a slow IPO market and traditional financing sources limited, companies turned to alternative capital solutions and innovative deal frameworks to advance pipelines and achieve strategic objectives.

In this environment, acquirers are prioritizing assets with credible commercialization pathways and reduced development risk. Given this focus, creative deal structuring helps reduce risk and protect value.

Market Trends and Deal Activity

Recent market activity reflects a continued shift away from traditional exit pathways toward hybrid M&A and collaboration-oriented models. Structures such as option-to-acquire arrangements, staged investments, and royalty monetization have become more prevalent, enabling parties to bridge valuation gaps and align incentives across development milestones.

While large pharmaceutical companies remain active acquirers, recent deal performance has been mixed, underscoring the importance of rigorous diligence and disciplined valuation approaches.

Cross-border considerations remain central to transaction planning. Regulatory developments in the European Union are reshaping the pharmaceutical landscape, while China’s emergence as a leading center of biopharmaceutical innovation, supported by accelerated development timelines and lower clinical costs, is driving increased cross-border collaboration, licensing, and acquisition activity.

Artificial intelligence (AI) and machine learning (ML) continue to be relevant to the industry as more biopharmaceutical and biotech companies consider how AI/ML can be integrated into their day-to-day operations to aid existing workstreams and improve productivity. There continues to be a focus on developing, investing in, and collaborating with AI/ML-supported target discovery and drug discovery platforms.  

Key Structural Considerations in Life Sciences Transactions

Life sciences transactions present distinct complexities arising from both the nature of the underlying assets and the industry’s highly interconnected ecosystem. Assets are frequently developed through successive academic and commercial collaborations, resulting in layered licensing frameworks and “upstream” agreements.

These arrangements often impose ongoing obligations, including intellectual property rights, data-sharing requirements, and financial entitlements, that may bind downstream acquirers and materially affect transaction value and structure. As a result, due diligence frequently includes a comprehensive assessment of contractual arrangements, regulatory requirements, and potential constraints on development and commercialization of the underlying assets.

Economic Terms and Risk Allocation

Transaction economics in the life sciences sector are closely aligned with the development stage and risk profile of the relevant asset. Early-stage programs typically involve lower upfront consideration supplemented by earnout/milestone-based and royalty-driven payments, reflecting significant clinical and regulatory uncertainty. Conversely, late-stage or commercial assets may command higher upfront valuations and reduced reliance on contingent consideration.

Hybrid transaction structures combining elements of acquisition and licensing are increasingly being deployed to allocate risk, preserve optionality, and facilitate continued development. In parallel, royalty monetization strategies, including synthetic royalty arrangements, are gaining traction as a means of securing nondilutive capital while maintaining long-term economic participation.

Biopharmaceutical companies and other established life science companies are using these royalty monetization strategies to extract value to further develop the asset subject to the royalty monetization traction or deploy elsewhere in their pipeline.

Key Takeaways

Life sciences M&A requires a highly specialized, multidisciplinary approach and carefully calibrated transaction structures. Given the centrality of intangible assets and prevalence of contingent value, parties should undertake comprehensive diligence of upstream agreements, regulatory frameworks, and commercialization strategies.

While risk cannot be eliminated, thoughtful structuring and proactive legal guidance are essential to mitigating exposure and successfully executing transactions in a complex and dynamic market environment.